Forest Labs News

Analyst Report ) reported a net loss of 14 cents per share in the third quarter, 6 cents better than the Zacks Consensus Estimate of a net loss of 20 cents.

All News and Columns >>>> Forest Laboratories, Inc. and its subsidiaries develop, manufacture and sell both branded and generic forms of ethical drug products, which require a physician's prescription.

I have written about Forest Laboratories, Inc. before. FRX is a mid-cap player in the biotech and drug markets.

GS_googleAddAdSenseService ; GS_googleEnableAllServices(); GA_googleUseIframeRendering(); _head> _script> NEWS Latest Archives Auto Cells, etc.

Ironwood Pharmaceuticals Inc. and partner Forest Laboratories Inc. reported positive results from two pivotal Phase III trials of its bowel drug candidate linaclotide in chronic constipation.

Ironwood Pharmaceuticals, Inc. and Forest Laboratories, Inc. today announced positive top-line results from two Phase 3 clinical trials assessing the safety and efficacy of once-daily dosing of the investigational drug linaclotide in patients with chronic constipation .

On the surface, Mylan 's earnings report wasn't pretty. Revenue fell by 24%, and the company lost $0.13 per share.

This morning, Forest Laboratories, Inc. , reported earnings per share of 85 cents for the second quarter of fiscal 2010, in-line with the Zacks Consensus Estimate.

The Mumbai-based drug firm has settled the matter with Forest Labs and has opted out of the case going on in the district court of Delaware, USA.

Forest Laboratories Inc. on Tuesday said its fiscal second-quarter profit fell 24 percent after it paid $100 million for the rights to market a chronic lung drug candidate.

Pretend you're the CEO of a drug company approaching the dreaded "patent cliff." Products yielding significant sales will soon face generic competition, but you don't know if your home-grown drugs can pick up the slack.

WE BELIEVE THAT Forest Laboratories shares can outperform the market by 15% over the next 12 months, and we are raising our investment rating to Outperform [from Neutral]. Nonconsensus, positive feedback on multiple Forest pipeline drugs from our physician and regulatory consultants at our recent Therapeutic Categories conference improves our ...

Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets.

Drugmaker Forest Laboratories Inc posted a lower-than-expected quarterly profit on Tuesday and gave an outlook below analysts' forecasts, sending shares down 4.8 percent.

BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors has Healthcare stock news and updates to its calendar database of Clinical Trials and upcoming FDA approvals & decisions.

Ian Sanderson - Cowen & Co. Tim Chiang - FTN Ronny Gal - Sanford Bernstein & Co.

MGM Mirage Inc., /quotes/comstock/13*!mgm /quotes/nls/mgm the Las Vegas casino and hotels operator, expects to report a third-quarter pretax charge of $955 million before taxes for impairment of its investment in CityCenter, a project on the Las Vegas Strip that's scheduled to open late this year.

NEW YORK & SAN DIEGO - Forest Laboratories, Inc. and Cypress Bioscience, Inc. today announced that Savella 100 mg/day demonstrated statistically significant and clinically meaningful concurrent improvements in pain, patient global assessment, and physical function, according to results from a large-scale, Phase III clinical trial that will be ...

There are times when clinical data crosses the wire and you do a double take, not quite believing what you're seeing.

Investor expectations for Targacept's experimental depression drug are moving higher in lockstep with the company's stock price as a key data presentation nears.